TheracosBio and SmithRx Collaborate to Offer Newly Approved Diabetes Drug Brenzavvy™ (bexagliflozin) to Members with Type 2 Diabetes
Retrieved on:
Thursday, August 17, 2023
Software, Biotechnology, Pharmaceutical, Health, Diabetes, Data Management, Health Technology, Technology, Diabetic neuropathy, Type 2 diabetes, Tenderness, Glycosuria, Dialysis, Gangrene, Pain, Urinary tract infection, 1946 Antarctica PBM Mariner crash, Incidence, Patient, Risk, PBM, Insulin, Ulcer, Pancreatitis, Diet, Cardiovascular disease, Urination, Vomiting, Cost Plus Drugs, Hypoglycemia, FDA, Death, Exercise, World Market (store), Chronic kidney disease, Amputation, Creatinine, Hypotension, Dehydration, Metabolic acidosis, Fever, CVD, Osteomyelitis, History, Abdominal pain, Ischemia, Erythema, Swelling, Type, Moyamoya disease, Knee, Infection, Pyelonephritis, Elijah Cummings Lower Drug Costs Now Act, Partnership, Hospital, Necrotizing fasciitis, Diabetic ketoacidosis, Pharmacy, Perineum, SGLT2, Ketoacidosis, Acute kidney injury, Frenz, Nausea, Female, Pharmaceutical industry, Dietary supplement, Medical imaging, Meat
Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.
Key Points:
- Working with TheracosBio and Cost Plus Drugs, SmithRx now provides BRENZAVVY as an option following its launch in July 2023.
- BRENZAVVY is not recommended for use to improve glycemic control in patients with type 1 diabetes mellitus.
- Diabetes is the most expensive chronic condition in the U.S. and accounts for 1 of every 4 dollars spent on healthcare.
- In patients with type 1 diabetes mellitus, BRENZAVVY significantly increases the risk of diabetic ketoacidosis, a life-threatening event, beyond background rate.